New strategic partnership with Ono Pharmaceutical to speed up delivery of new treatments for dementia

We are pleased to announce a new strategic industry partnership with Ono Pharmaceutical Co., Ltd. (Ono), alongside the funding of multiple projects. Delivering innovative research that translates into improvements in diagnosis and treatment of dementia is central to the mission of the UK DRI, and industry partnerships have a crucial role to play.

Ono is an R&D-oriented pharmaceutical company focused on drug discovery and development, aiming to identify and develop innovative and breakthrough medications for diseases with a high unmet medical need. Neurology and neurodegenerative disease research are key priorities for Ono, and the company aims to drive forward research in this area, bringing disease modifying therapies to patients.

Dr Kay Penicud, UK DRI Director of Innovation & Business, said:

“We are delighted to partner with Ono Pharma, a company that shares our commitment to developing life-changing new drugs for dementia. This strategic collaboration leverages our complementary capabilities in discovery research and drug development. By working together, we aim to accelerate the translation of new research into clinical applications that will bring us closer to desperately needed treatments for those affected by dementia.”

Dr. Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono, said:

“We are pleased to collaborate with UK DRI which has world-leading research capabilities and research collaborative framework. We expect that this partnership will lead to the discovery of innovative new therapeutic targets for dementia.”

Industry partnerships are vital to the UK DRI’s mission, helping us to achieve maximum impact through our research. Find out more about our other strategic partnerships.

Article published: 20 December 2023
Banner image: Ono Pharmaceutical